GlassScriptPhysician profile
Alicja Matusiak
NPI 1174757678
$10,882.40
in general payments reported to CMS, 2019-2025
19 companies · $2,115 in 2025
The $2,115 reported for 2025 was more than what 93% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,413 · 2022: $3,051 · 2023: $1,634 · 2024: $1,669 · 2025: $2,115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,094 · Education: $324.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,094.21 |
| Education | $324.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $2,266.83 | 2021-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Abbvie INC. | $1,800.63 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,504.48 | 2021-2025 | Caplyta |
| Alkermes, INC. | $1,294.75 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $1,090.36 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Neurocrine Biosciences, INC. | $808.13 | 2021-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $686.26 | 2023-2025 | Auvelity |
| Sunovion Pharmaceuticals INC. | $334.04 | 2021-2022 | |
| Lundbeck LLC | $281.14 | 2021-2025 | Rexulti |
| Tris Pharma INC | $207.30 | 2022-2025 | Dyanavel Xr, Quillichew Er, Quillivant |
| Janssen Pharmaceuticals, INC | $167.86 | 2022-2023 | Spravato |
| Vanda Pharmaceuticals INC. | $138.21 | 2021-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $137.76 | 2022-2025 | Trintellix |
| Noven Therapeutics, LLC | $47.64 | 2021-2024 | Xelstrym |
| Noven Pharmaceuticals, INC. | $38.33 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $25.43 | 2025 | Loreev Xr |
| E.R. Squibb & Sons, L.L.C. | $20.74 | 2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $19.54 | 2024 | Qelbree |
| Bausch Health US, LLC | $12.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alicja Matusiak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.